Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis

Table 1 Characteristics of included studies

Study	Year	Country	No.	Cancer type	Design	Follow-up	Cut-off	Outcome	Treatment	HR source	NOS
Huang [14]	2019	China	458 (328 [training] + 130 [validation])^a	Cervical cancer (FIGO stage I, II)	R, multi-center	47 m	475	OS, LNM, LVI	Surgery	M	9
Nie [11]	2019	China	533 (250 [training] + 283 [validation])^a	Ovarian cancer (FIGO stage I-IV)	R, multi-center	46 m	612	OS, PFS, LNM	Surgery	M	9
Farolfi [15]	2018	Italy	375	Ovarian cancer (FIGO stage III-IV)	R, multi-center	43 m	730	OS, PFS	Chemotherapy	M	7
De Giorgi [16]	2019	USA	516	Breast cancer (triple-negative, HER2+, HER2– ER+)	R, single-center	–	836	OS	Systemic treatment	Overall (U), subtype (M)	8
Liu [12]	2019	China	160	Triple-negative breast cancer	R, single-center	61.7 m	557	OS, DFS	Surgery, chemotherapy, radiotherapy	M	8
Sun [21]	2019	China	155	Hormone receptor-HER2 + breast cancer	R, single-center	57.6 m	578	OS, DFS, LNM	Surgery, chemotherapy, radiotherapy	M	9
Li [22]	2019	China	161	Luminal breast cancer	R, single-center	28.4 m	518	DFS, LNM, LVI	Surgery, chemotherapy, radiotherapy, endocrine therapy	M	9
Wang [13]	2019	China	215	Triple-negative breast cancer	R, single-center	49.2 m	624	OS, DFS, LNM	Surgery, chemotherapy, radiotherapy	M	9
Holub [20]	2019	Spain	151	Cervical cancer (FIGO stages I–IV)	R, single-center	43.8 m	1000	OS	Surgery, chemotherapy, radiotherapy	U	9

FIGO International Federation of Obstetrics and Gynecology, HER2 epidermal growth factor receptor type 2 ER estrogen receptor, R retrospective, m month, OS overall survival, PFS progression-free survival, DFS disease-free survival, DMFS distant metastasis-free survival, LNM lymph node metastasis, LVI lymphovascular invasion, HR hazard ratio, M multivariate, U univariate
^aIncluding the training and validation cohorts

ISSN: 1477-7819